Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy

Tiffany Devine, Mushui Dai

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Within the past decade, there has been a revolution in the types of drugs developed to treat cancer. Therapies that selectively target cancer-specific aberrations, such as kinase inhibitors, have made a dramatic impact on a subset of patients. In spite of these successes, there is still a dearth of treatment options for the vast majority of patients. Therefore, there is a need to design therapies with broader efficacy. The p53 tumor suppressor pathway is one of the most frequently altered in human cancers. However, about half of all cancers retain wild-type p53, yet through various mechanisms, the p53 pathway is otherwise inactivated. Targeting this pathway for reactivation truly represents the "holy" grail in cancer treatment. Most commonly, destabilization of p53 by various components of ubiquitin-proteasome system, notably the ubiquitin ligase MDM2 and its partner MDMX as well as various deubiquitinating enzymes (DUBs), render p53 inert and unresponsive to stress signals. Reinstating its function in cancer has been a long sought-after goal. Towards this end, a great deal of work has been devoted to the development of compounds that either interfere with the p53-MDM2 and p53-MDMX interactions, inhibit MDM2 E3 activity, or target individual DUBs. Here we review the current progress that has been made in the field, with a special emphasis on both MDM2 and DUB inhibitors. Developing inhibitors targeting the upstream of the p53 ubiquitination pathway will likely also be a valuable option.

Original languageEnglish (US)
Pages (from-to)3248-3262
Number of pages15
JournalCurrent Pharmaceutical Design
Volume19
Issue number18
DOIs
StatePublished - 2013

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Neoplasms
Therapeutics
Ubiquitination
Ligases
Phosphotransferases
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Cell cycle
  • Deubiquitinating enzyme
  • MDM2
  • MDMX
  • p53
  • Proteasome
  • Ubiquitin ligase
  • Ubiquitination

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. / Devine, Tiffany; Dai, Mushui.

In: Current Pharmaceutical Design, Vol. 19, No. 18, 2013, p. 3248-3262.

Research output: Contribution to journalArticle

@article{3d23b7023fc84e7583b01fc9eedd296f,
title = "Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy",
abstract = "Within the past decade, there has been a revolution in the types of drugs developed to treat cancer. Therapies that selectively target cancer-specific aberrations, such as kinase inhibitors, have made a dramatic impact on a subset of patients. In spite of these successes, there is still a dearth of treatment options for the vast majority of patients. Therefore, there is a need to design therapies with broader efficacy. The p53 tumor suppressor pathway is one of the most frequently altered in human cancers. However, about half of all cancers retain wild-type p53, yet through various mechanisms, the p53 pathway is otherwise inactivated. Targeting this pathway for reactivation truly represents the {"}holy{"} grail in cancer treatment. Most commonly, destabilization of p53 by various components of ubiquitin-proteasome system, notably the ubiquitin ligase MDM2 and its partner MDMX as well as various deubiquitinating enzymes (DUBs), render p53 inert and unresponsive to stress signals. Reinstating its function in cancer has been a long sought-after goal. Towards this end, a great deal of work has been devoted to the development of compounds that either interfere with the p53-MDM2 and p53-MDMX interactions, inhibit MDM2 E3 activity, or target individual DUBs. Here we review the current progress that has been made in the field, with a special emphasis on both MDM2 and DUB inhibitors. Developing inhibitors targeting the upstream of the p53 ubiquitination pathway will likely also be a valuable option.",
keywords = "Apoptosis, Cell cycle, Deubiquitinating enzyme, MDM2, MDMX, p53, Proteasome, Ubiquitin ligase, Ubiquitination",
author = "Tiffany Devine and Mushui Dai",
year = "2013",
doi = "10.2174/1381612811319180009",
language = "English (US)",
volume = "19",
pages = "3248--3262",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "18",

}

TY - JOUR

T1 - Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy

AU - Devine, Tiffany

AU - Dai, Mushui

PY - 2013

Y1 - 2013

N2 - Within the past decade, there has been a revolution in the types of drugs developed to treat cancer. Therapies that selectively target cancer-specific aberrations, such as kinase inhibitors, have made a dramatic impact on a subset of patients. In spite of these successes, there is still a dearth of treatment options for the vast majority of patients. Therefore, there is a need to design therapies with broader efficacy. The p53 tumor suppressor pathway is one of the most frequently altered in human cancers. However, about half of all cancers retain wild-type p53, yet through various mechanisms, the p53 pathway is otherwise inactivated. Targeting this pathway for reactivation truly represents the "holy" grail in cancer treatment. Most commonly, destabilization of p53 by various components of ubiquitin-proteasome system, notably the ubiquitin ligase MDM2 and its partner MDMX as well as various deubiquitinating enzymes (DUBs), render p53 inert and unresponsive to stress signals. Reinstating its function in cancer has been a long sought-after goal. Towards this end, a great deal of work has been devoted to the development of compounds that either interfere with the p53-MDM2 and p53-MDMX interactions, inhibit MDM2 E3 activity, or target individual DUBs. Here we review the current progress that has been made in the field, with a special emphasis on both MDM2 and DUB inhibitors. Developing inhibitors targeting the upstream of the p53 ubiquitination pathway will likely also be a valuable option.

AB - Within the past decade, there has been a revolution in the types of drugs developed to treat cancer. Therapies that selectively target cancer-specific aberrations, such as kinase inhibitors, have made a dramatic impact on a subset of patients. In spite of these successes, there is still a dearth of treatment options for the vast majority of patients. Therefore, there is a need to design therapies with broader efficacy. The p53 tumor suppressor pathway is one of the most frequently altered in human cancers. However, about half of all cancers retain wild-type p53, yet through various mechanisms, the p53 pathway is otherwise inactivated. Targeting this pathway for reactivation truly represents the "holy" grail in cancer treatment. Most commonly, destabilization of p53 by various components of ubiquitin-proteasome system, notably the ubiquitin ligase MDM2 and its partner MDMX as well as various deubiquitinating enzymes (DUBs), render p53 inert and unresponsive to stress signals. Reinstating its function in cancer has been a long sought-after goal. Towards this end, a great deal of work has been devoted to the development of compounds that either interfere with the p53-MDM2 and p53-MDMX interactions, inhibit MDM2 E3 activity, or target individual DUBs. Here we review the current progress that has been made in the field, with a special emphasis on both MDM2 and DUB inhibitors. Developing inhibitors targeting the upstream of the p53 ubiquitination pathway will likely also be a valuable option.

KW - Apoptosis

KW - Cell cycle

KW - Deubiquitinating enzyme

KW - MDM2

KW - MDMX

KW - p53

KW - Proteasome

KW - Ubiquitin ligase

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=84878825727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878825727&partnerID=8YFLogxK

U2 - 10.2174/1381612811319180009

DO - 10.2174/1381612811319180009

M3 - Article

VL - 19

SP - 3248

EP - 3262

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 18

ER -